# ⚔️ GTM STRATEGY - COMPLETE CONSOLIDATION ⚔️

**Date**: January 13, 2025  
**Status**: ✅ **CONSOLIDATED SOURCE OF TRUTH**  
**Consolidated From**:
- `GTM_STRATEGY_SUMMARY.md` - Revenue pipeline strategy
- `JR1_PRE_SEEDING_CHECKLIST.md` - Trial seeding checklist
- `../rules/CrisPRO_Command_Center/3_Outreach/Lead_Gen_System/AGENT_JR2_GTM_MISSION.md` - JR2 lead gen mission

---

## 📚 TABLE OF CONTENTS

1. [Executive Summary](#executive-summary)
2. [The Strategic Insight](#the-strategic-insight)
3. [The Numbers](#the-numbers)
4. [JR1: Trial Seeding](#jr1-trial-seeding)
5. [JR2: GTM Automation](#jr2-gtm-automation)
6. [Revenue Pipeline](#revenue-pipeline)
7. [References to Archived Files](#references-to-archived-files)

---

## 🎯 EXECUTIVE SUMMARY

**Mission**: Turn 200 seeded trials into 600 qualified leads → $1-2M revenue pipeline

**The Logic**:
1. JR1 seeds 200 frontline ovarian cancer trials into AstraDB
2. Each trial = potential customer (sponsor, PI, CRO, site coordinator)
3. JR2 parses metadata → extracts 600+ contacts → generates 200 custom 1-pagers → launches mass outreach
4. **Result**: 600 leads → 30-60 responses → 15-30 meetings → 3-6 pilots → **$1.25M-$2.5M (18-24 months)**

**Timeline**: 3 weeks (parallel with Ayesha work)

---

## 🎯 THE STRATEGIC INSIGHT

**We're not just helping Ayesha find trials - we're turning those 200 trials into our GTM pipeline!**

**The GTM Flywheel**:
```
JR1 Seeds 200 Trials
    ↓
JR2 Parses Trial Metadata
    ↓
JR2 Generates Custom 1-Pagers (mass automation)
    ↓
JR2 Extracts Contact Info (sponsors, PIs, sites)
    ↓
JR2 Generates Personalized Emails
    ↓
Mass Outreach (200 targets)
    ↓
Track Responses → CRM Pipeline
```

---

## 📊 THE NUMBERS

### **Input:**
- 200 trials seeded by JR1 (frontline ovarian cancer)
- Avg 3 contacts per trial (sponsor, PI, site coordinator)
- **= 600 qualified leads**

### **Conversion Funnel (Conservative Estimates):**
- **600 emails sent** (50/day over 12 days)
- **40-50% open rate** → 240-300 opens
- **5-10% response rate** → 30-60 replies
- **50% meeting conversion** → 15-30 discovery calls
- **20% pilot conversion** → 3-6 no-cost pilots

### **Revenue Pipeline (18-24 months):**
- **3-6 pilots** (no cost, proof-of-concept)
- **1-2 convert to $250K prospective** → $250K-$500K
- **1-2 convert to $1M platform license** → $1M-$2M
- **Total: $1.25M-$2.5M** from 200 trials

---

## 🔧 JR1: TRIAL SEEDING

**Owner**: Agent JR1  
**Mission**: Seed 200 frontline ovarian cancer trials into AstraDB  
**Timeline**: 2-3 hours  
**Status**: 🔄 **IN PROGRESS**

### **Pre-Seeding Checklist**:

**1. AstraDB Schema Verification**:
- ✅ Required fields for clinical use (trial_id, title, phase, status, interventions, eligibility, locations)
- ❓ NEW fields needed for GTM (sponsor_name, sponsor_contact_email, PI_name, PI_email, primary_endpoint, mechanism_tags, biomarker_requirements, site_count, estimated_enrollment)

**2. Parsing Logic for GTM Fields**:
- Source: ClinicalTrials.gov API (`https://clinicaltrials.gov/api/v2/studies`)
- Parse: Sponsor, contacts, primary endpoint, enrollment, site count
- Store: Add GTM fields to AstraDB schema before seeding

**3. Seeding Script**:
- Check if AstraDB already has ≥200 ovarian trials
- If not, seed from ClinicalTrials.gov API
- Filter: Frontline, Stage IV, Recruiting, Ovarian cancer

**Full Checklist**: See `JR1_PRE_SEEDING_CHECKLIST.md` (273 lines)

---

## 🚀 JR2: GTM AUTOMATION

**Owner**: Agent JR2  
**Mission**: Mass 1-pager generation + outreach automation  
**Timeline**: 1 week (after JR1 completes)  
**Status**: ⏸️ **AWAITING JR1**

### **What JR2 Will Build**:

**System 1: Trial-Specific 1-Pager Generator**
- Input: Trial metadata from AstraDB
- Output: Customized PDF + web page (200 total)
- Features: Trial-specific content, partnership options, analytics tracking

**System 2: Contact Extraction & Enrichment**
- Sources: ClinicalTrials.gov API, LinkedIn, Hunter.io/RocketReach
- Output: CSV with 600+ contacts (sponsors, PIs, site coordinators)
- Priority: HIGH (sponsor decision-makers, lead PIs), MEDIUM (site coordinators)

**System 3: Personalized Email Generator**
- 3 variants per contact (Technical, Business, Patient-Centric)
- A/B testing: Subject lines, CTAs, personalization depth
- Tracking: Open rates, click rates, response rates

**System 4: CRM Pipeline Integration**
- Track: Email sent → Opened → Clicked → Replied → Meeting → Pilot
- Metrics: Conversion rates, time-to-response, pipeline velocity
- Alerts: High-value leads, fast responders, decision-makers

**Full Mission**: See `../rules/CrisPRO_Command_Center/3_Outreach/Lead_Gen_System/AGENT_JR2_GTM_MISSION.md` (590 lines)

---

## 💰 REVENUE PIPELINE

### **Tier 1: Retrospective Pilot (No Cost)**
- **Value**: Proof-of-concept, 20 patients, 4 weeks
- **Goal**: Demonstrate value, build trust
- **Conversion**: 3-6 pilots from 15-30 meetings

### **Tier 2: Prospective Integration ($250K)**
- **Value**: Real-time scoring, 50-100 patients
- **Goal**: Validate in live trial
- **Conversion**: 1-2 from 3-6 pilots

### **Tier 3: Platform License ($1-5M/year)**
- **Value**: Unlimited analyses across all trials
- **Goal**: Long-term partnership
- **Conversion**: 1-2 from 1-2 Tier 2 deals

### **Total Revenue (18-24 months)**:
- **Conservative**: $1.25M (1 Tier 2 + 1 Tier 3)
- **Aggressive**: $2.5M (2 Tier 2 + 2 Tier 3)

---

## 📖 REFERENCES TO ARCHIVED FILES

All original GTM strategy files have been preserved:

- **GTM Strategy Summary**: `GTM_STRATEGY_SUMMARY.md` (keep as reference)
- **JR1 Checklist**: `JR1_PRE_SEEDING_CHECKLIST.md` (keep as reference)
- **JR2 Mission**: `../rules/CrisPRO_Command_Center/3_Outreach/Lead_Gen_System/AGENT_JR2_GTM_MISSION.md` (keep as reference)

---

## ⚔️ DOCTRINE STATUS: ACTIVE

**LAST UPDATED:** January 13, 2025  
**APPLIES TO:** All GTM strategy, lead generation, and revenue pipeline planning  
**ENFORCEMENT:** Mandatory for all GTM execution and agent assignments

**This master document represents the complete consolidation of all GTM strategy. Every plan, checklist, and mission brief is preserved and organized for maximum clarity and actionability.**

